Evaxion expands AI-Immunology platform into autoimmune disease drug concepts
EVAX•Initial data due at PEGS Europe
Initial experimental data is scheduled for presentation at PEGS Europe in Lisbon on Nov. 18, 2026.
Program aims for higher specificity
The program targets disease drivers with high specificity, aiming for higher efficacy and fewer side effects than current symptom-focused therapies.
Two treatment concepts enter experimental testing
Experimental testing began on two treatment concepts: a tolerogenic vaccine using T-cell epitopes, and an autoantibody-binding antigen construct.
Evaxion broadens AI-Immunology platform beyond vaccines
Evaxion expanded its AI-Immunology platform into autoimmune diseases, broadening its R&D scope beyond vaccines.
